Evidence map›Paper›PMID 36342853›Full record

ArticleDiabetes technology & therapeutics2023

Progressive Acceleration of Insulin Exposure Over 7 Days of Infusion Set Wear.

Jasmin R Kastner, Timothy S Bailey, Poul Strange, Leon Shi, Keith A Oberg, Paul J Strasma, Jeffrey I Joseph, Douglas B Muchmore

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes technology & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Insulin Delivery Hardware: Pumps and Pens.Diabetes technology & therapeutics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Jasmin R KastnerThe Artificial Pancreas Center, Department of Anesthesiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-0821-3778
Timothy S BaileyAMCR Institute, Escondido, California, USA.ORCID 0000-0003-4178-3462
Poul StrangeIntegrated Medical Development, Princeton Junction, New Jersey, USA.
Leon ShiIntegrated Medical Development, Princeton Junction, New Jersey, USA.
Keith A ObergOrthogonal Concept Consulting, Valencia, California, USA.
Paul J StrasmaCapillary Biomedical, Inc., Irvine, California, USA.
Jeffrey I JosephThe Artificial Pancreas Center, Department of Anesthesiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Douglas B MuchmoreCapillary Biomedical, Inc., Irvine, California, USA.
MP Biomedicals (United States) · USThomas Jefferson University · USUniversity Medical Center of Princeton · USAMCR Institute · USOrthogonal (United States) · US

Funding

Relative Bioavailability of Subcutaneous Insulin over Extended Durations of Infusion Set UseR44DK110969 · NIDDK · CAPILLARY BIOMEDICAL, INC. · PI STRASMA, PAUL J · 2018 to 2018
$1.8M
Multi-Orifice Continuous Subcutaneous Insulin Infusion Catheter with Reduced Pharmacokinetic Variability and Rapid On-Off Pharmacodynamic ActionsR43DK110969 · NIDDK · CAPILLARY BIOMEDICAL, INC. · PI STRASMA, PAUL J · 2016 to 2017
$269k
NIDDK NIH HHS R43 DK110969NIDDK NIH HHS R44 DK110969
6 · The paper itself

Abstract

Insulin exposure varies over 3 days of insulin infusion set (IIS) wear making day-to-day insulin dosing challenging for people with diabetes (PWD). Here we report insulin pharmacodynamic (PD) and pharmacokinetic (PK) data extending these observations to 7 days of IIS wear. PWD (A1C ≤8.5%, C-peptide <0.6 nmol/L, ≥6 months pump use) were enrolled in a crossover euglycemic clamp pilot study comparing conventional Teflon angled IISs with an investigational extended-wear IIS. PK/PD data from six participants were obtained for 5 h postbolus. Although PD data were unstable, PK profiles (pooled data from both groups) of insulin lispro (0.15 U/kg bolus) showed statistically significant progressive decreases from days 0 to 7 for

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 1Blood GlucoseCross-Over StudiesGlucose Clamp TechniqueHumansHypoglycemic AgentsInsulinInsulin Infusion SystemsInsulin LisproInsulin, Regular, HumanPilot ProjectsBlood GlucoseHypoglycemic AgentsInsulinInsulin LisproInsulin, Regular, HumanEuglycemic clampExtended-wear insulin infusion setsInsulin pharmacokineticsType 1 diabetes

Identifiers

PMID36342853
PMCPMC9894594
OpenAlexW4308365615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.